CTLA4 and cancer: Immune-checkpoint inhibitors (ICIs) target these cancer proteins aiming at preventing the binding with their partners located at the plasma membrane of immune system cells, such as cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), programmed cell death 1 (PD-1), and its ligand, PD-L1 [91].